RELA

Quality 0.50 · 2 views · Updated 2 months ago

Protein-coding gene in the species Homo sapiens

title: "RELA" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["transcription-factors"] description: "Protein-coding gene in the species Homo sapiens" topic_path: "arts/film" source: "https://en.wikipedia.org/wiki/RELA" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Protein-coding gene in the species Homo sapiens ::

::callout[type=note]

Transcription factor p65 also known as nuclear factor NF-kappa-B p65 subunit is a protein that in humans is encoded by the RELA gene.

RELA, also known as p65, is a REL-associated protein involved in NF-κB heterodimer formation, nuclear translocation and activation. NF-κB is an essential transcription factor complex involved in all types of cellular processes, including cellular metabolism, chemotaxis, etc. Phosphorylation and acetylation of RELA are crucial post-translational modifications required for NF-κB activation. RELA has also been shown to modulate immune responses, and activation of RELA is positively associated with multiple types of cancer.

Gene and expression

RELA, or v-rel avian reticuloendotheliosis viral oncogene homolog A, is also known as p65 or NFKB3. It is located on chromosome 11 q13, and its nucleotide sequence is 1473 nucleotide long. RELA protein has four isoforms, the longest and the predominant one being 551 amino acids. RELA is expressed alongside p50 in various cell types, including epithelial/endothelial cells and neuronal tissues.

Structure

RELA is one member of the NF-κB family, one of the essential transcription factors under intensive study. Seven proteins encoded by five genes are involved in the NF-κB complex, namely p105, p100, p50, p52, RELA, c-REL and RELB. Like other proteins in this complex, RELA contains a N-terminal REL-homology domain (RHD), and also a C-terminal transactivation domain (TAD). RHD is involved in DNA binding, dimerization and NF-κB/REL inhibitor interaction. On the other hand, TAD is responsible for interacting with the basal transcription complex including many coactivators of transcription such as TBP, TFIIB and CREB-CBP. RELA and p50 is the mostly commonly found heterodimer complex among NF-κB homodimers and heterodimers, and is the functional component participating in nuclear translocation and activation of NF-κB.

RELA is a 65 kDa protein.

Phosphorylation

Phosphorylation of RELA plays a key role in regulating NF-κB activation and function. Subsequent to NF-κB nuclear translocation, RELA undergoes site-specific post-translational modifications to further enhance the NF-κB function as a transcription factor. RELA can either be phosphorylated in the RHD region or the TAD region, attracting different interaction partners. Triggered by lipopolysaccharide (LPS), protein kinase A (PKA) specifically phosphorylates serine 276 in the RHD domain in the cytoplasm, controlling NF-κB DNA-binding and oligomerization. On the other hand, mitogen and stress-activated kinase 1 (MSK1) are also able to phosphorylate RELA at residue 276 under TNFα induction in the nucleus, increasing NF-κB response at the transcriptional level. Two residues in the TAD region are targeted by phosphorylation. After IL-1or TNFα stimulation, serine 529 is phosphorylated by casein kinase II (CKII), while serine 536 is phosphorylated by IκB kinases (IKKs). In response to DNA damage, ribosomal subunit kinase-1 (RSK1) also has the ability to phosphorylate RELA at serine 536 in a p53-dependent manner. A couple of other kinases are also able to phosphorylate RELA at different conditions, including glycogen-synthase kinase-3β (GSK3β), AKT/phosphatidylinositol 3-kinase (PI3K) and NF-κB activating kinase (NAK, i.e. TANK-binding kinase-1 (TBK1) and TRAF2-associated kinase (T2K)). The fact that RELA can be modified by a collection of kinases via phosphorylation at different sites/regions within the protein under different stimulations might suggest a synergistic effect of these modifications. Phosphorylation at these sites enhances NF-κB transcriptional response via tightened binding to transcription coactivators. For example, CBP and p300 binding to RELA are enhanced when serine 276 or 311 is phosphorylated. Status of several phosphorylation sites determines RELA stability mediated by the ubiquitin-mediated proteolysis. Cell-type-specific phosphorylation is also observed for RELA. Multiple-site phosphorylation is common in endothelial cells, and different cell types may contain different stimuli, leading to targeted phosphorylation of RELA by different kinases. For instance, IKK2 is found to be mainly responsible for phosphorylating serine 536 in monocytes and macrophages, or in CD40 receptor binding in hepatic stellate cells. IKK1 functions as the major kinase phosphorylating serine 536 under different stimuli, such as the ligand activation of the lymphotoxin-β receptor (LTβR).

Acetylation

In vivo studies revealed that RELA is also under acetylation modification in the nucleus, which is just as important as phosphorylation as a post-translational modification of proteins. Lysines 218, 221 and 310 are acetylation targets within RELA, and response to acetylation is site-specific. For instance, lysine 221 acetylation facilitates RELA dissociation from IκBα and enhances its DNA-binding affinity. Lysine 310 acetylation is indispensable for the full transcriptional activity of RELA, but does not affect its DNA-binding ability. Hypothesis about RELA acetylation suggests acetylation aids its subsequent recognition by transcriptional co-activators with bromodomains, which are specialized in recognizing acetylated lysine residues. Lysine 122 and 123 acetylation are found to be negatively correlated with RELA transcriptional activation. Unknown mechanisms mediate the acetylation of RELA possibly using p300/CBP and p300/CBP factor associated coactivators under TNFα or phorbol myristate acetate (PMF) stimulation both in vivo and in vitro. RELA is also under the control of deacetylation via HDAC, and HDAC3 is the mediator of this process both in vivo and in vitro.

Methylation

Methylation of lysine 218 and 221 together or lysine 37 alone in the RHD domain of RELA can lead to increased response to cytokines such as IL-1 in mammalian cell culture.

Interactions

As the prototypical heterodimer complex member of the NF-κB, together with p50, RELA/p65 interacts with various proteins in both the cytoplasm and in the nucleus during the process of classical NF-κB activation and nuclear translocation. In the inactive state, RELA/p50 complex is mainly sequestered by IκBα in the cytosol. TNFα, LPS and other factors serve as activation inducers, followed by phosphorylation at residue 32 and 36 of IκBα, leading to rapid degradation of IκBα via the ubiquitin-proteasomal system and subsequent release of RELA/p50 complex. RELA nuclear localization signal used to be sequestered by IκBα is now exposed, and rapid translocation of the NF-κB occurs. In parallel, there is a non-classical NF-κB activation pathway involving the proteolytic cleavage of p100 into p52 instead of p50. This process does not require RELA, hence will not be discussed in detail here. After NF-κB nuclear localization due to TNFα stimulation, p50/RELA heterodimer will function as a transcription factor and bind to a variety of genes involved in all kinds of biological processes, such as leukocyte activation/chemotaxis, negative regulation of TNFIKK pathway, cellular metabolism, antigen processing, just to name a few . Phosphorylation of RELA at different residues also enables its interaction with CDKs and P-TEFb. Phosphorylation at serine 276 in RELA allows its interaction with P-TEFb containing CDK9 and cyclin T1 subunits, and phospho-ser276 RELA-P-TEFb complex is necessary for IL-8 and Gro-β activation. Another mechanism is involved in the activation of genes preloaded with Pol II in a RELA serine 276 phosphorylation independent manner.

RELA has been shown to interact with:

Role in immune system

Gene knockout of NF-κB genes via homologous recombination in mice showed the role of these components in innate and adaptive immune responses. RELA knockout mice is embryonic lethal due to liver apoptosis. Lymphocyte activation failure is also observed, suggesting that RELA is indispensable in the proper development of the immune system. In comparison, deletion of other REL-related genes will not cause embryonic development failure, though different levels of defects are also noted. The fact that cytokines such as TNFα and IL-1 can stimulate the activation of RELA also supports its participation in immune response. In general, RELA participates in adaptive immunity and responses to invading pathogens via NF-κB activation. Mice without individual NF-κB proteins are deficient in B- and T-cell activation and proliferation, cytokine production and isotype switching. Mutations in RELA is found responsible for inflammatory bowel disease as well.

Cancer

NF-κB/RELA activation has been found to be correlated with cancer development, suggesting the potential of RELA as a cancer biomarker. Specific modification patterns of RELA have also been observed in many cancer types.

Prostate

RELA may have a potential role as biomarker for prostate cancer progression and metastases, as suggested by the association found between RELA nuclear localization and prostate cancer aggressiveness and biochemical recurrence.

Thyroid

Strong correlation between nuclear localization of RELA and clinicopathological parameters for papillary thyroid carcinoma (PTC), suggesting the role of NF-κB activation in tumor growth and aggressiveness in PTC. Other than usage as a biomarker, serine 536 phosphorylation in RELA is also correlated with nuclear translocation and the expression of some transactivating genes such as COX-2, IL-8 and GST-pi in follicular thyroid carcinomas via morphoproteomic analysis.

Leukemia

Mutations in the transactivation domain of RELA can lead to decrease in transactivating ability and this mutation can be found in lymphoid neoplasia.

Head and neck

Nuclear localization of NF-κB/RELA is positively correlated with tumor micrometastases into lymph and blood and negatively correlated with patient survival outcome in patients with head and neck squamous cell carcinoma (HNSCC). This suggests a role of NF-κB/RELA as a possible target for targeted-therapy.

Breast

There is both a physical and a functional association between RELA and aryl hydrocarbon receptor (AhR), and the subsequent activation of c-myc gene transcription in breast cancer cells.

Monogenic Behçet's Disease-like conditions

Behçet's disease-like conditions are increasingly recognized and to date predominantly involve loss-of-function variants in TNFAIP3. However, a RELA mutation that results in truncated protein variant has been reported to cause severe autoinflammatory disease due to impaired NF-κB signaling and increased apoptosis. The phenotypes associated with this disease include mucocutaneous ulcerative syndrome and neuromyelitis optica (NMO).

References

(March 1991). "DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide". Cell.
(June 2021). "Chromatin-embedded reporter genes: Quantification of stimulus-induced gene transcription". Gene.
"RELA v-rel avian reticuloendotheliosis viral oncogene homolog A [Homo sapiens (human)]". National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine.
(2006-11-14). "Homo sapiens p65 gene for p65 subunit of transcription factor NF-kappa". National Center for Biotechnology Information (NCBI), U.S. National Library of Medicine.
(October 2002). "NF-kappaB regulation in the immune system". Nature Reviews. Immunology.
(May 2004). "Shaping the nuclear action of NF-kappaB". Nature Reviews. Molecular Cell Biology.
(May 1999). "Regulation of NF-kappaB RelA phosphorylation and transcriptional activity by p21(ras) and protein kinase Czeta in primary endothelial cells". The Journal of Biological Chemistry.
(April 1998). "Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300". Molecular Cell.
(August 2003). "Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation". The EMBO Journal.
(October 2000). "Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II". The Journal of Biological Chemistry.
(June 2004). "p53 induces NF-kappaB activation by an IkappaB kinase-independent mechanism involving phosphorylation of p65 by ribosomal S6 kinase 1". The Journal of Biological Chemistry.
(December 2003). "Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA". Molecular Cell.
(April 2009). "Phosphorylation of NF-kappaB p65 at Ser468 controls its COMMD1-dependent ubiquitination and target gene-specific proteasomal elimination". EMBO Reports.
(April 2010). "Pim-1 controls NF-kappaB signalling by stabilizing RelA/p65". Cell Death and Differentiation.
(August 2013). "Role of lysine methylation of NF-κB in differential gene regulation". Proceedings of the National Academy of Sciences of the United States of America.
(June 2008). "RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes". Molecular and Cellular Biology.
(April 2000). "PDZ domain-dependent suppression of NF-kappaB/p65-induced Abeta42 production by a neuron-specific X11-like protein". The Journal of Biological Chemistry.
(November 2000). "The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells". Oncogene.
(September 2002). "2,3,7,8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-alpha and anti-CD40-induced activation of NF-kappaB/Rel in dendritic cells: p50 homodimer activation is not affected". Molecular Pharmacology.
(July 2002). "Novel transcription coactivator complex containing activating signal cointegrator 1". Molecular and Cellular Biology.
(July 2003). "BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit". The Journal of Biological Chemistry.
(February 1999). "Signal-induced ubiquitination of IkappaBalpha by the F-box protein Slimb/beta-TrCP". Genes & Development.
(September 1999). "ERK MAP kinase links cytokine signals to activation of latent HIV-1 infection by stimulating a cooperative interaction of AP-1 and NF-kappaB". The Journal of Biological Chemistry.
"Molecular Interaction Database".
(August 2002). "Interplay between cdk9 and NF-kappaB factors determines the level of HIV-1 gene transcription in astrocytic cells". Oncogene.
(June 2003). "Transcriptional inhibition of interleukin-8 expression in tumor necrosis factor-tolerant cells: evidence for involvement of C/EBP beta". The Journal of Biological Chemistry.
(December 1997). "Cross-talk between transcription factors NF-kappa B and C/EBP in the transcriptional regulation of genes". The International Journal of Biochemistry & Cell Biology.
(May 2007). "Modulation of DNA binding properties of CCAAT/enhancer binding protein epsilon by heterodimer formation and interactions with NFkappaB pathway". Blood.
(June 2004). "PIAS3 suppresses NF-kappaB-mediated transcription by interacting with the p65/RelA subunit". The Journal of Biological Chemistry.
(March 2002). "The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1". Molecular Cell.
(December 1997). "Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription". Journal of Immunology.
(March 1998). "CREB-binding protein in androgen receptor-mediated signaling". Proceedings of the National Academy of Sciences of the United States of America.
(April 1997). "CREB-binding protein/p300 are transcriptional coactivators of p65". Proceedings of the National Academy of Sciences of the United States of America.
(June 2012). "Monoubiquitination of nuclear RelA negatively regulates NF-κB activity independent of proteasomal degradation". Cellular and Molecular Life Sciences.
(October 2000). "Tumor necrosis factor alpha-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II". The Journal of Biological Chemistry.
(September 2004). "RNA helicase A interacts with nuclear factor kappaB p65 and functions as a transcriptional coactivator". European Journal of Biochemistry.
(October 2002). "A novel protein overexpressed in hepatoma accelerates export of NF-kappa B from the nucleus and inhibits p53-dependent apoptosis". Cancer Cell.
(April 2001). "Involvement of the pro-oncoprotein TLS (translocated in liposarcoma) in nuclear factor-kappa B p65-mediated transcription as a coactivator". The Journal of Biological Chemistry.
(April 2009). "GCN5 is a required cofactor for a ubiquitin ligase that targets NF-kappaB/RelA". Genes & Development.
(October 2001). "The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression". Molecular and Cellular Biology.
(August 2002). "Histone deacetylases augment cytokine induction of the iNOS gene". Journal of the American Society of Nephrology.
(March 2004). "The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis". Nature.
(January 2003). "Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65". The Journal of Biological Chemistry.
(August 2001). "Duration of nuclear NF-kappaB action regulated by reversible acetylation". Science.
(May 2001). "Interaction between hnRNPA1 and IkappaBalpha is required for maximal activation of NF-kappaB-dependent transcription". Molecular and Cellular Biology.
(April 1994). "Purification, reconstitution, and I kappa B association of the c-Rel-p65 (RelA) complex, a strong activator of transcription". Molecular and Cellular Biology.
(September 1998). "Ikappa Balpha functions through direct contacts with the nuclear localization signals and the DNA binding sequences of NF-kappaB". The Journal of Biological Chemistry.
(September 1998). "IKAP is a scaffold protein of the IkappaB kinase complex". Nature.
(Aug 2014). "Krüppel-like factor 5 mediates proinflammatory cytokine expression in lipopolysaccharide-induced acute lung injury through upregulation of nuclear factor-κB phosphorylation in vitro and in vivo". Mediators of Inflammation.
(August 2013). "A novel mechanism of crosstalk between the p53 and NFκB pathways: MDM2 binds and inhibits p65RelA". Cell Cycle.
(August 2001). "The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation". Oncogene.
(March 2003). "Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1)". The EMBO Journal.
(June 2002). "Myotrophin/V-1, a protein up-regulated in the failing human heart and in postnatal cerebellum, converts NFkappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimers". The Journal of Biological Chemistry.
(May 2003). "p47phox participates in activation of RelA in endothelial cells". The Journal of Biological Chemistry.
(September 1996). "Mutual transcriptional interference between RelA and androgen receptor". The Journal of Biological Chemistry.
(February 2004). "A physical and functional map of the human TNF-alpha/NF-kappa B signal transduction pathway". Nature Cell Biology.
(October 1993). "NF-kappa B p100 (Lyt-10) is a component of H2TF1 and can function as an I kappa B-like molecule". Molecular and Cellular Biology.
(June 2003). "KappaB-Ras binds to the unique insert within the ankyrin repeat domain of IkappaBbeta and regulates cytoplasmic retention of IkappaBbeta x NF-kappaB complexes". The Journal of Biological Chemistry.
(October 1996). "Role of unphosphorylated, newly synthesized I kappa B beta in persistent activation of NF-kappa B". Molecular and Cellular Biology.
(October 1997). "A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription". Molecular and Cellular Biology.
(January 1994). "Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor". Proceedings of the National Academy of Sciences of the United States of America.
(September 2000). "The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain". Genes & Development.
(April 1995). "Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids". Molecular Endocrinology.
(February 2003). "IkappaBalpha and p65 regulate the cytoplasmic shuttling of nuclear corepressors: cross-talk between Notch and NFkappaB pathways". Molecular Biology of the Cell.
(April 2000). "Silencing mediator of retinoic acid and thyroid hormone receptors, as a novel transcriptional corepressor molecule of activating protein-1, nuclear factor-kappaB, and serum response factor". The Journal of Biological Chemistry.
(December 2001). "The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function". The Journal of Biological Chemistry.
(June 2007). "PDLIM2-mediated termination of transcription factor NF-kappaB activation by intranuclear sequestration and degradation of the p65 subunit". Nature Immunology.
(September 2010). "A-kinase-interacting protein 1 (AKIP1) acts as a molecular determinant of PKA in NF-kappaB signaling". The Journal of Biological Chemistry.
(May 2002). "Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NF(-kappa)B transcription factors". Human Molecular Genetics.
(December 2012). "PPARγ is an E3 ligase that induces the degradation of NFκB/p65". Nature Communications.
(May 1999). "Identification of a novel inhibitor of nuclear factor-kappaB, RelA-associated inhibitor". The Journal of Biological Chemistry.
(August 2002). "RelA-associated inhibitor blocks transcription of human immunodeficiency virus type 1 by inhibiting NF-kappaB and Sp1 actions". Journal of Virology.
(October 2001). "Targeted disruption of the zetaPKC gene results in the impairment of the NF-kappaB pathway". Molecular Cell.
(May 2002). "Mutational analysis of the v-Rel dimerization interface reveals a critical role for v-Rel homodimers in transformation". Journal of Virology.
(January 2003). "Regulation of RelA (p65) function by the large subunit of replication factor C". Molecular and Cellular Biology.
(July 2003). "RING finger protein AO7 supports NF-kappaB-mediated transcription by interacting with the transactivation domain of the p65 subunit". The Journal of Biological Chemistry.
(June 2004). "Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase". The EMBO Journal.
(March 2011). "Suppressor of cytokine signaling 1 (SOCS1) limits NFkappaB signaling by decreasing p65 stability within the cell nucleus". FASEB Journal.
(January 2007). "COMMD1 promotes the ubiquitination of NF-kappaB subunits through a cullin-containing ubiquitin ligase". The EMBO Journal.
(July 2002). "NF-kappaB induced by IL-1beta inhibits elastin transcription and myofibroblast phenotype". American Journal of Physiology. Cell Physiology.
(November 1994). "Interaction of the v-Rel oncoprotein with cellular transcription factor Sp1". Journal of Virology.
(October 2002). "Signal transducers and activators of transcription 3 (STAT3) inhibits transcription of the inducible nitric oxide synthase gene by interacting with nuclear factor kappaB". The Biochemical Journal.
(September 1998). "TAFII105 mediates activation of anti-apoptotic genes by NF-kappaB". The EMBO Journal.
(June 1998). "Involvement of TFIID and USA components in transcriptional activation of the human immunodeficiency virus promoter by NF-kappaB and Sp1". Molecular and Cellular Biology.
(March 1995). "Interaction of the COOH-terminal transactivation domain of p65 NF-kappa B with TATA-binding protein, transcription factor IIB, and coactivators". The Journal of Biological Chemistry.
(June 2010). "High-throughput sequencing identifies STAT3 as the DNA-associated factor for p53-NF-kappaB-complex-dependent gene expression in human heart failure". Genome Medicine.
(July 2003). "SINK is a p65-interacting negative regulator of NF-kappaB-dependent transcription". The Journal of Biological Chemistry.
(February 2019). "Roles of DNA repair enzyme OGG1 in innate immunity and its significance for lung cancer". Elsevier.
(January 2018). "RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging". Brain Tumor Pathology.
(February 2019). "Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma". Science Signaling.
(July 2017). "O-GlcNAcylation of NF-κB Promotes Lung Metastasis of Cervical Cancer Cells via Upregulation of CXCR4 Expression". Molecules and Cells.
(July 2013). "Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer". European Journal of Cancer.
(April 2013). "Activation of nuclear factor-κB contributes to growth and aggressiveness of papillary thyroid carcinoma". Pathology, Research and Practice.
(2012). "Morphoproteomic confirmation of an activated nuclear factor-кBp65 pathway in follicular thyroid carcinoma". International Journal of Clinical and Experimental Pathology.
(February 1997). "Identification of a tumor-associated mutant form of the NF-kappaB RelA gene with reduced DNA-binding and transactivating activities". Oncogene.
(July 2013). "Nuclear NF-κB expression correlates with outcome among patients with head and neck squamous cell carcinoma treated with primary chemoradiation therapy". International Journal of Radiation Oncology, Biology, Physics.
(June 2009). "NF-kappaB and estrogen receptor alpha interactions: Differential function in estrogen receptor-negative and -positive hormone-independent breast cancer cells". Journal of Cellular Biochemistry.
(March 2021). "A Novel RELA Truncating Mutation in a Familial Behçet's Disease-like Mucocutaneous Ulcerative Condition". Arthritis & Rheumatology.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::